Laquinimod

Drug Profile

Laquinimod

Alternative Names: ABR-215062; Laquinimod sodium; Nerventra; SAIK-MS; TV-5600

Latest Information Update: 31 May 2017

Price : $50

At a glance

  • Originator Active Biotech
  • Developer Icahn School of Medicine at Mount Sinai; National University of Singapore; Ruhr-University Bochum; Tel Aviv University; Teva Pharmaceutical Industries; University College London; University of British Columbia
  • Class Quinolones; Small molecules
  • Mechanism of Action Aryl hydrocarbon receptor agonists; Brain-derived neurotrophic factor expression stimulants; Immunomodulators; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Multiple sclerosis
  • Phase II Crohn's disease; Huntington's disease
  • No development reported Lupus nephritis
  • Discontinued Systemic lupus erythematosus

Most Recent Events

  • 19 Apr 2017 Teva Pharmaceutical completes the phase III CONCERTO trial for Multiple sclerosis in US, Canada, Albania, Bosnia-Herzegovina, Croatia, Latvia, Macedonia, Moldova, Montenegro, Serbia, the UK, Chile, Mexico, Puerto Rico, Belarus, Georgia, Israel, Kazakhstan, Russia, South Africa, South Korea, Ukraine, Austria, Bulgaria, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Poland, Romania, Slovakia, Belgium, Latvia, Poland and Spain(NCT01707992)
  • 16 Feb 2017 Laquinimod receives Orphan Drug status for Huntington's disease in USA before February 2017
  • 19 Sep 2016 The USFDA rescinds the Special Protocol Assessment for the phase III CONCERTO trial
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top